Ovation.io and Illumina Unite for Genomic Progress
Ovation.io, Inc., an innovative organization committed to creating superior multi-omics datasets, has recently announced an exciting collaboration with Illumina, Inc. (NASDAQ: ILMN). As a leading entity in DNA sequencing and array-based technologies, Illumina aims to revolutionize precision medicine through this partnership. Together, they are tackling the challenges faced in drug development by leveraging the immense potential of genomic data. This fusion of expertise will facilitate the discovery of drug targets and biomarkers that promise to enhance the probability of success while simultaneously reducing development costs.
Collaboration Focus and Goals
The primary emphasis of this collaboration lies in non-oncology indications where there is a lack of clinical-genomic datasets essential for advancing genomically-based research. By utilizing Illumina’s state-of-the-art next-generation sequencing (NGS) platforms alongside Ovation’s comprehensive biobank, which boasts over 1.6 million de-identified and consented samples, researchers will benefit from high-quality genomic data connected to extensive and longitudinal clinical data. This data will include electronic medical records, laboratory results, and claims, thereby providing a well-rounded foundation for research.
Driving Innovation in Research
The groundbreaking work carried out during this collaboration aims to significantly enhance the identification of optimal targets across various medical conditions. By improving existing treatment options and paving the way for developing novel therapeutics, the partnership stands to make substantial contributions to the field of genomic medicine.
Building on Existing Products
This partnership will further enhance Ovation’s current IBD Omics product, which features whole genome sequencing and RNA-seq tailored for patients with Inflammatory Bowel Diseases (IBD). This innovative product is designed to pinpoint novel biomarkers associated with disease progression and therapeutic responses in both Crohn’s Disease and Ulcerative Colitis.
Phased Approaches to Collaboration
The first phase of this collaboration will focus on generating pilot datasets concerning liver disease, chronic kidney disease, and patients undergoing treatment with glucagon-like peptide-1 (GLP-1) receptor agonists. The objective is to showcase the quality, depth, and diversity of the data emerging from Ovation's extensive biobank. Following this, both Ovation and Illumina plan to seek partnerships within the industry to sequence underrepresented patient populations that carry high value for research.
Testimonials from Leadership
"Harnessing human genomic data has already brought about transformative personalized medicines, particularly in oncology and rare disease research. Our collaboration with Ovation is set to enrich the diversity and depth of data available, making a significant difference in metabolic diseases, cardiology, immunology, and beyond," said Todd Christian, senior vice president of Services, Arrays, and Genomic Access businesses at Illumina. He expressed confidence that these collaborations align with Illumina's mission to expand genomic healthcare insights across a wider array of conditions and accelerate the advancements of precision medicines.
Reflecting on the impact of this collaboration, Curt Medeiros, the CEO of Ovation, stated, "Partnering with Illumina marks a pivotal milestone in our objective to revolutionize the accessibility and utility of genomic data for researchers. By merging Illumina’s top-tier sequencing expertise with our advanced platform designed for acquiring large volumes of consented patient samples, we can expand our partnership far beyond the initial 1.6 million samples in the Ovation biobank. This will greatly increase the volume of genomic data available for research purposes."
About Ovation
Ovation is a forward-thinking genomic data company dedicated to unlocking the full potential of human genomic data and accelerating the development of precision medicine. Through the provision of high-quality genomic data that is interconnected with rich, longitudinal phenotypic data, Ovation enables life sciences researchers to advance the processes of drug discovery and development with greater efficiency.
By utilizing a cloud-based Laboratory Information Management System (LIMS) alongside the Ovation Research Network, the company empowers a diverse array of clinical laboratories to embrace innovative molecular testing swiftly. Furthermore, they facilitate the biobanking and transformation of samples intended for research pursuits.
Frequently Asked Questions
What is the main goal of the Ovation.io and Illumina collaboration?
The main goal is to enhance drug development efficiencies and precision medicine advancements by leveraging genomic data.
How does Illumina contribute to this partnership?
Illumina provides its cutting-edge NGS platforms, enabling the generation of high-quality genomic datasets.
What kind of diseases will this collaboration focus on initially?
The initial focus will be on liver disease, chronic kidney disease, and patients treated with GLP-1 receptor agonists.
How does Ovation’s biobank benefit researchers?
Ovation’s biobank offers access to a vast repository of over 1.6 million consented samples linked to comprehensive clinical data, boosting research potential.
What is the impact of this collaboration on the future of genomic research?
This collaboration is expected to significantly improve the quality and diversity of data available, fostering advancements in multiple medical fields.
